SYSTEMATIC REVIEW OF DENGUE VACCINE EFFICACY
DOI:
https://doi.org/10.53555/rh1cdn33Keywords:
Dengue fever, dengue vaccine, dengue virusAbstract
Background: Dengue fever belongs to the arboviruses which are the genus Flavivirus (family Flaviridae) and is transmitted through female mosquitoes that carry the dengue virus. There are four serotypes of dengue fever, namely DENV−1, DENV−2, DENV−3, and DENV−4. The number of cases of dengue fever infection is estimated at 390 million spread across 128 countries. Although globally, only 3.2 million cases were reported to WHO in 2015. There are many challenges in developing a safe and effective dengue fever vaccine. Infection with one of the four dengue virus serotypes has been shown to provide long-term protection against homotypic reinfection, but protection against secondary heterotypic infection is only temporary.
The aim: This study aims to show about dengue vaccine efficacy.
Methods: By comparing itself to the standards set by the Preferred Reporting Items for Systematic Review and MetaAnalysis (PRISMA) 2020, this study was able to show that it met all of the requirements. So, the experts were able to make sure that the study was as up-to-date as it was possible to be. For this search approach, publications that came out between 2013 and 2023 were taken into account. Several different online reference sources, like Pubmed and SagePub, were used to do this. It was decided not to take into account review pieces, works that had already been published, or works that were only half done.
Result: In the PubMed database, the results of our search brought up 83 articles, whereas the results of our search on SagePub brought up 147 articles. The results of the search conducted for the last year of 2013 yielded a total 79 articles for PubMed and 90 articles for SagePub. The result from title screening, a total 31 articles for PubMed and 24 articles for SagePub. In the end, we compiled a total of 7 papers. We included five research that met the criteria.
Conclusion: Dengue vaccines can be produced with live attenuated chimeric recombinant viruses, live attenuated viruses, inactivated viruses, recombinant proteins and mRNA vaccines. Each of these vaccines has good efficacy in terms of protection against dengue virus.
References
Jamjoom GA, Azhar EI, Kao MA, Radadi RM. Seroepidemiology of asymptomatic dengue virus infection in Jeddah, Saudi Arabia. Virol Res Treat. 2016;2016(7):1–7.
Harapan H, Michie A, Mudatsir M, Sasmono RT, Imrie A. Epidemiology of dengue hemorrhagic fever in Indonesia:
Analysis of five decades data from the National Disease Surveillance. BMC Res Notes [Internet] 2019;12(1):4–9. Available from: https://doi.org/10.1186/s13104-019-4379-9
Rivera L, Biswal S, Sáez-Llorens X, Reynales H, López-Medina E, Borja-Tabora C, et al. Three-year Efficacy and Safety of Takeda’s Dengue Vaccine Candidate (TAK-003). Clin Infect Dis. 2022;75(1):107–17.
Godói IP, Lemos LLP, De Araújo VE, Bonoto BC, Godman B, Guerra Júnior AA. CYD-TDV dengue vaccine: Systematic review and meta-analysis of efficacy, immunogenicity and safety. J Comp Eff Res. 2017;6(2):165–80.
Hadinegoro SR, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, et al. Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. N Engl J Med. 2015;373(13):1195–206.
Villar L, Dayan GH, Arredondo-García JL, Rivera DM, Cunha R, Deseda C, et al. Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America. N Engl J Med. 2015;372(2):113–23.
Thomas R, Chansinghakul D, Limkittikul K, Gilbert PB, Hattasingh W, Moodie Z, et al. Associations of human leukocyte antigen with neutralizing antibody titers in a tetravalent dengue vaccine phase 2 efficacy trial in Thailand. Hum Immunol [Internet] 2022;83(1):53–60. Available from: https://doi.org/10.1016/j.humimm.2021.09.006
Reynales H, Carrasquilla G, Zambrano B, Cortés S M, MacHabert T, Jing J, et al. Secondary Analysis of the Efficacy and Safety Trial Data of the Tetravalent Dengue Vaccine in Children and Adolescents in Colombia. Pediatr Infect Dis J. 2020;39(4):30–6.
Moodie Z, Juraska M, Huang Y, Zhuang Y, Fong Y, Carpp LN, et al. Neutralizing antibody correlates analysis of tetravalent dengue vaccine efficacy trials in Asia and Latin America. J Infect Dis. 2018;217(5):742–53.
Plennevaux E, Moureau A, Arredondo-García JL, Villar L, Pitisuttithum P, Tran NH, et al. Impact of Dengue Vaccination on Serological Diagnosis: Insights from Phase III Dengue Vaccine Efficacy Trials. Clin Infect Dis. 2018;66(8):1164–72.
Savarino SJ, Bonaparte M, Wang H, Dayan GH, Forrat R, Zhu M, et al. Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with a new dengue rapid diagnostic test: a retrospective analysis of phase 3 efficacy trials. The Lancet Microbe. 2022;3(6):e427–34.
Ndii MZ, Mage AR, Messakh JJ, Djahi BS. Optimal vaccination strategy for dengue transmission in Kupang city, Indonesia. Heliyon [Internet] 2020;6(11):e05345. Available from: https://doi.org/10.1016/j.heliyon.2020.e05345
Dorigatti I, Donnelly CA, Laydon DJ, Small R, Jackson N, Coudeville L, et al. Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning. Nat Commun. 2018;9(1).
Dinakaran D, Sreeraj VS, Venkatasubramanian G. Dengue and Psychiatry: Manifestations, Mechanisms, and Management Options. Indian J Psychol Med. 2022;44(5):429–35.
Silva JP, Fernandez-Sesma A. Challenges on the development of a dengue vaccine: a comprehensive review of the state of the art. J Gen Virol. 2023;104(3):1–12.
Tully D, Griffiths CL. Dengvaxia: the world’s first vaccine for prevention of secondary dengue. Ther Adv Vaccines Immunother. 2021;9:1–8.
Kariyawasam R, Lachman M, Mansuri S, Chakrabarti S, Boggild AK. A dengue vaccine whirlwind update. Ther Adv Infect Dis. 2023;10:1–6.
Sáez-Llorens X, Biswal S, Borja-Tabora C, Fernando LK, Liu M, Wallace D, et al. Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue. Am J Trop Med Hyg. 2023;108(4):722–6.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
